Ms. Rebecca Chan, a former senior executive of the Listing Division of the Hong Kong Stock Exchange and ex-partners of three out of four big four international firms, joins Cloudbreak Pharma as the Chief Financial Officer
Cloudbreak Pharma is pleased to announce that Ms. Rebecca Chan has joined as the group’s Chief Financial Officer. Rebecca’s contributions will be instrumental to Cloudbreak Pharma’s future development. Ms. Rebecca Chan has over 34 years of working experience in international accounting firms and the Hong Kong Stock Exchange. She has served as a partner of […]
Cloudbreak completed Phase 2 Clinical Trial for CBT-006 in the U.S. for the treatment of Meibomian Gland Dysfunction associated Dry Eye Disease
Cloudbreak Pharma has announced that the last patient has exited the study of the Phase 2 clinical trial in the U.S on May 17, 2022 for CBT-006, a new drug for the treatment of dry eye disease caused by meibomian gland dysfunction. The results of the Phase 2 clinical trial are expected to be officially […]
Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-004
Irvine, CA – February 18, 2021 – Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-004 to treat vascularized pinguecula. The Phase 2 […]
Cloudbreak Receives U.S. Food and Drug Administration Clearance to Proceed with Clinical Study using Investigational New Drug CBT-006
Irvine, CA – November 30, 2020 – Cloudbreak Therapeutics, a clinical-stage company focused on developing innovative therapies for diseases and conditions of the eye, had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2 study using Investigational New Drug (IND) CBT-006 to treat Meibomian Gland Dysfunction Associated Dry […]
